You are here: Industry Insights > Neurotrope

News List

Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer prnasia
June 09, 2021
Travecta Therapeutics, Pte Ltd. incorporated in Singapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of ...
Neurotrope, Metuchen Announce Merger Completion Forming Petros americanpharmaceuticalreview
December 23, 2020
Neurotrope and Metuchen Pharmaceuticals have announced the completion of their previously announced merger following the satisfaction of all closing conditions required by the amended merger agreement.
Neurotrope Announces First Patient Dosed in Bryostatin Trial for Alzheimer's Disease americanpharmaceuticalreview
October 12, 2020
Neurotrope has announced the dosing of the first patient in its ongoing, long-term Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease (AD).
BryoLogyx Acquires Rights to Neurotrope’s Bryostatin-1 contractpharma
June 16, 2020
Bryostatin-1 will be chemically synthesized by Albany Molecular Research Inc. (AMRI) in collaboration with BryoLogyx.
Neurotrope, NIH Launch Clinical Trial of Bryostatin for Alzheimer's Disease americanpharmaceuticalreview
June 08, 2020
Neurotrope announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD).
Bryostatin-1 Study Does Not Meet Primary Endpoint americanpharmaceuticalreview
September 10, 2019
Neurotrope announced its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance on the primary endpoint...
Neurotrope Concludes Data Collection in Alzheimer's Disease Clinical Trial americanpharmaceuticalreview
July 16, 2019
Neurotrope announced that the Company has concluded data collection in its confirmatory Phase 2 double blind, placebo controlled clinical trial of Bryostatin-1 in the treatment of moderately severe to severe AD.
Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel firstwordpharma
April 21, 2019
Neurotrope, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases……
Neurotrope Announces Agreement for Bryostatin-1 with National Cancer Institute americanpharmaceuticalreview
February 19, 2019
Neurotrope has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.....